Roxana Mehran, MD
Cardiovascular Disease · New York, NYNPI 1447203401
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $276,337 of the $432,032 with a category attached, or 64.0%. 28 manufacturers reported payments, led by Novo Nordisk AS at 39.2% of the total. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $1728.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$169K
- Medtronic$41K
- Sanofi US Services Inc.$40K
- Novartis$26K
- Janssen Research & Development, LLC$23K
- Bayer$22K
- plus $111K from 22 others
Across 183 payments — averaging $32,825 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.6M
- Astrazeneca UK Limited$2.5M
- CSL Behring$235K
- Janssen Scientific Affairs, LLC$131K
- Janssen Research & Development, LLC$111K
- Medtronic$90K
- plus $298K from 7 others
What the payments were for
- Consulting fees$276,33764%
- Speaking & faculty fees$79,75718%
- Travel & lodging$60,09614%
- Food & beverage$7,5752%
- Education$2250%
- Ownership interest$8,0432%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 35 | $169,146 |
| Medtronic(2 entities) | 56 | $41,311 |
| Sanofi US Services Inc. | 4 | $40,437 |
| Novartis | 22 | $25,595 |
| Janssen Research & Development, LLC | 23 | $22,879 |
| Bayer | 13 | $21,908 |
| CSL Behring | 15 | $19,059 |
| Edwards Lifesciences | 12 | $15,460 |
| Daiichi Sankyo Inc. | 9 | $14,340 |
| Daiichi Sankyo Company LTD | 3 | $14,065 |
| Cordis US CORP. | 6 | $12,030 |
| Boston Scientific | 3 | $8,203 |
| Abbott | 11 | $6,791 |
| Chiesi USA, Inc. | 2 | $4,337 |
| Amgen | 6 | $3,973 |
| Idorsia Pharmaceuticals US Inc | 8 | $3,244 |
| Penumbra, Inc. | 5 | $2,427 |
| Recor Medical Inc | 2 | $1,812 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,572 |
| Philips North America LLC | 2 | $1,350 |
| Janssen Scientific Affairs, LLC | 1 | $1,000 |
| Novo Nordisk | 2 | $417 |
| Jenavalve Technology, Inc. | 1 | $185 |
| Cleerly, Inc. | 1 | $156 |
| Biotronik Inc. | 1 | $154 |
| Boehringer Ingelheim International GmbH | 2 | $113 |
| GE HealthCare | 1 | $49 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$30,447
- Savaysa$13,292
- XARELTO$12,340
- LEQVIO$10,042
- cardio$8,130
- GENERAL - THERAPIES$8,043
- Xience V coronary stent system$4,800
- SELUTION SLRPCTA$3,900
- Repatha$3,850
- SELATOGREL$3,150
- Indigo System$2,328
- PARADISE RENAL DENERVATION SYSTEM$1,800
- (9520) IGT Devices Undivided$1,350
- PRESSUREWIRE$1,300
- Ultreon$204
- DRAGONFLY OPSTAR$176
- Octopus$172
- Cleerly Ischemia$156
- Cleerly Labs$156
- PK Papyrus$154
How this compares
$432,032 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $268,202 |
| Rosuvastatin Calcium | 71 | $1,007 |
| Losartan Potassium | 36 | $582 |
| Metoprolol Succinate | 12 | $191 |
| Atorvastatin Calcium | 13 | $176 |
| Amlodipine Besylate | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
- Steven MarxNew York$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.